Regencell Bioscience Holdings Limited (RGC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Regencell Bioscience Holdings Limited (RGC) is down 47.2% since the beginning of the year. At $11 per share, RGC is trading 83.9% below its 52-week high of $69.

Regencell Bioscience Holdings Limited (RGC) has returned -47.24% so far this year and -53.25% over the past 12 months.

Based on dividend-adjusted daily data since Jul 16, 2021, RGC's average daily return is +0.96%, while the average monthly return is +36.84%. At this rate, an investment would double in approximately 0.2 years.

Historically, 47% of months were positive and 53% were negative. The best month was May 2025 with a return of +1,361.7%, while the worst month was Jun 2025 at -98.1%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, RGC closed higher 38% of trading days. The best single day was Jul 23, 2024 with a return of +343.9%, while the worst single day was Jun 16, 2025 at -89.9%.

Regencell Bioscience Holdings Limited has an annualized alpha of 990.37%, beta of 0.17, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 16, 2021.

• This stock tended to rise when S&P 500 Index fell (downside capture of -960.07%), but participation in market rallies was also limited (-106.64%) - a profile typical of counter-cyclical assets.
• Beta of 0.17 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RGC ranks 31 for risk / return — below 31% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Regencell Bioscience Holdings Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Regencell Bioscience Holdings Limited was 98.82%, occurring on Jul 2, 2025. The portfolio has not yet recovered.

The current Regencell Bioscience Holdings Limited drawdown is 98.74%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Regencell Bioscience Holdings Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Regencell Bioscience Holdings Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.